Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT02586857 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)

StatusActive, Not Recruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. 5 versions Re-verified since Mar 11, 2025, no change to tracked fieldsv25-v29
  2. Completion date: Dec 31, 2025 to Apr 1, 2026v24
  3. 7 versions Re-verified since Nov 4, 2022, no change to tracked fieldsv17-v23
  4. Site details revised at 1 of 7 sitesv16
  5. 3 versions Re-verified since Oct 15, 2021, no change to tracked fieldsv13-v15
Show 11 earlier versionsHide 11 earlier versions
  1. Study Status, References, Document Sectionv12
  2. Re-verified, no change to tracked fieldsv11
  3. Primary completion date: Mar 29, 2018 to Jun 26, 2020 Completion date: Jun 5, 2025 to Dec 31, 2025 · Start date: Jan 2016 to Jan 25, 2016 · Eligibility criteria expanded, about 235 words · 2 morev10 Show 5 more changesShow less
    • Completion date: Jun 5, 2025 to Dec 31, 2025
    • Start date: Jan 2016 to Jan 25, 2016
    • Eligibility criteria expanded, about 235 words
    • Study description expanded, about 34 words
    • Study sites revised (7)

    See this version in full on ClinicalTrials.gov ↗

  4. Results first posted: Jul 29, 2020 Primary endpoints: 2 to 1 · Enrollment target: estimated 52 to confirmed 24 · Primary completion date changed from estimate of Dec 2019 to Mar 29, 2018 · 2 morev9 Show 5 more changesShow less
    • Primary endpoints: 2 to 1
    • Enrollment target: estimated 52 to confirmed 24
    • Primary completion date changed from estimate of Dec 2019 to Mar 29, 2018
    • Completion date: Dec 2019 to Jun 5, 2025
    • Study arms: 1 to 2

    See this version in full on ClinicalTrials.gov ↗

  5. Primary and study completion dates: Jun 2018 to Dec 2019v8
  6. Trial status: Recruiting to Active, Not Recruiting Enrollment target: 72 to 52 · Primary completion date: Jan 2018 to Jun 2018 · Site details revised at 7 of 7 sitesv7 Show 3 more changesShow less
    • Enrollment target: 72 to 52
    • Primary completion date: Jan 2018 to Jun 2018
    • Site details revised at 7 of 7 sites
  7. Study sites: 1 to 7 Study arms: 2 to 1v6 Show 1 more changeShow less
    • Study arms: 2 to 1
  8. 3 versions Re-verified since Jun 28, 2016, no change to tracked fieldsv3-v5
  9. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 1 · Start date: Feb 2016 to Jan 2016 · Study description shortened, about 76 wordsv2 Show 3 more changesShow less
    • Study sites: 0 to 1
    • Start date: Feb 2016 to Jan 2016
    • Study description shortened, about 76 words

    See this version in full on ClinicalTrials.gov ↗

  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Acerta Pharma BV
17 trials monitored
See 1 trial at risk
Glioblastoma
670 trials monitored
See 44 trials at risk
A Phase 1b/2, Multicenter, Open-Label Study of ACP-196 in Subjects with Recurrent Glioblastoma Multiforme (GBM)
Trial Details
NCT Number NCT02586857
Lead Sponsor Acerta Pharma BV
Conditions Glioblastoma Multiforme
Enrollment 24 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov